Abstract:Background: Currently, no satisfactory biomarkers are available to screen for lung cancer. Surface-Enhanced Laser Desorption/ionization Time-of- Flight Mass Spectrometry ProteinChip system (SELDI-TOF-MS) is one of the currently used techniques to identify biomarkers for cancers. The aim of this study is to explore the application of serum SELDI proteomic patterns to distinguish lung cancer patients from healthy individuals.Methods: A total of 208 serum samples, including 158 lung cancer patients and 50 healthy individuals, were randomly divided into a training set (including 11 sera from patients with stages I/II lung cancer, 63 from patients with stages III/IV lung cancer and 20 from healthy controls) and a blinded test set (including 43 sera from patients with stages I/II lung cancer, 41 from patients with stages III/IV lung cancer and 30 from healthy controls). All samples were analyzed by SELDI technology. The spectra were generated on weak cation exchange (WCX2) chips, and protein peaks clustering and classification analyses were made using Ciphergen Biomarker Wizard and Biomarker Pattern software, respectively. We additionally determined Cyfra21-1 and NSE in the 208 serum samples included in this study using an electrochemiluminescent immunoassay.Results: Five protein peaks at 11493, 6429, 8245, 5335 and 2538 Da were automatically chosen as a biomarker pattern in the training set. When the SELDI marker pattern was tested with the blinded test set, it yielded a sensitivity of 86.9%, a specificity of 80.0% and a positive predictive value of 92.4%. The sensitivities provided by Cyfra21-1 and NSE used individually or in combination were significantly lower than that of the SELDI marker pattern (P < 0.005 or 0.05, respectively). Based on the results of the test set, we found that the SELDI marker pattern showed a sensitivity of 91.4% in the detection of non-small cell lung cancers (NSCLC), which was significantly higher than that in the detection of small cell lung cancers (P < 0.05); The pattern also had a sensitivity of 79.1% in the detection of lung cancers in stages I/II.Conclusion: These results suggest that serum SELDI protein profiling can distinguish lung cancer patients, especially NSCLC patients, from normal subjects with relatively high sensitivity and specificity, and the SELDI- TOF- MS is a potential tool for the screening of lung cancer.

Tree Analysis Pattern of Mass Spectral Urine Profiles in Differential Diagnosis of Bladder Transitional Cell Carcinoma

Tree Analysis of Mass Spectral Urine Profiles Discriminates Transitional Cell Carcinoma of the Bladder from Noncancer Patient

Using Tree Analysis Pattern and SELDI-TOF-MS to Discriminate Transitional Cell Carcinoma of the Bladder Cancer from Noncancer Patients

[Use of Laser Capture Microdissection and Surface-Enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Differential Proteins in Lung Adenocarcinoma and Lung Squamous Carcinoma].

Microfluidic Assaying of Circulating Tumor Cells and its Correlation with Muscle Invasiveness and Tumor Grade of Urothelial Bladder Cancer

Microfluidic Assaying of Circulating Tumor Cells and Its Application in Risk Stratification of Urothelial Bladder Cancer

SELDI-TOF-MS ProteinChip Technology for Screening of Urine Markers of Bladder Carcinoma

[Proteomic analysis in combination with CT diagnosis to distinguish renal cell carcinoma from renal benign masses]

Establishing a model of classification tree for stage I colorectal cancer using surface-enhanced laser desorption ionization time-of-flight mass spectrometry

Screening urine markers of renal cell carcinoma using SELDI-TOF-MS]

UPLC-Q-TOF/MS-based Urine Metabolomics for the Diagnosis and Staging of Bladder Cancer

Differential Expression of Proteomics Models of Colorectal Cancer, Colorectal Benign Disease and Healthy Controls

Diagnosis of Gastric Cancer Using Decision Tree Classification of Mass Spectral Data

Study of Distinct Protein Profiles for Early Diagnosis of NSCLC Using LCM and SELDI-TOF-MS

Application of Serum Seldi Proteomic Patterns in Diagnosis of Lung Cancer

Application of SELDI-TOF MS Spectrometry in Serological Diagnosis for Esophageal Squamous Cell Carcinoma

Bladder Cancer Determination Via Two Urinary Metabolites: A Biomarker Pattern Approach

Application of Serum Surface-Enhanced Laser Desorption/ionization Proteomic Patterns in Distinguishing Lung Cancer Patients from Healthy People.

Identification of Serum Biomarkers for Biliary Tract Cancers by a Proteomic Approach Based on Time-of-Flight Mass Spectrometry

Construction of the classification tree model of colorectal cancer with lymphatic metastasis by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

Urine-based SERS and multivariate statistical analysis for identification of non-muscle-invasive bladder cancer and muscle-invasive bladder cancer